Nurix announces detil-0255 scientific presentations at the 37th annual meeting of the society for immunotherapy of cancer (sitc) and successful completion of detil-0255 phase 1 safety run-in

Presentations highlight use of nurix's first-in-class cbl-b inhibitor nx-0255 to enhance growth and profile of t cells for cell therapy in detil-0255 program presentations highlight use of nurix's first-in-class cbl-b inhibitor nx-0255 to enhance growth and profile of t cells for cell therapy in detil-0255 program
NRIX Ratings Summary
NRIX Quant Ranking